Imuran (Azathioprine)

Azathioprine is a pro‑drug that is converted in the body to 6‑mercaptopurine. This metabolite interferes with the synthesis of purine nucleotides, which are essential for DNA, RNA and protein production in rapidly dividing lymphocytes. By limiting lymphocyte proliferation, azathioprine suppresses immune responses.

The dose of Imuran is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and laboratory monitoring results. Dosage adjustments are made to achieve therapeutic effect while minimizing toxicity, and patients should follow the prescriber’s written instructions.

Imuran is classified as Pregnancy Category D, indicating evidence of risk to the fetus; it should only be used when the potential benefit justifies the risk. Limited data are available for breastfeeding, and the drug may pass into breast milk, so continuation should be decided by the treating physician.

To place an order, submit an enquiry on the Imuran product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both azathioprine (Imuran) and mycophenolate mofetil are antimetabolite immunosuppressants that inhibit lymphocyte proliferation, but they act on different enzymes in the purine pathway. Mycophenolate generally has a more rapid onset and may be associated with higher rates of gastrointestinal side effects, while azathioprine is often chosen for its longer clinical experience and lower cost in many transplant protocols.

Imuran tablets should be stored at room temperature, below 25 °C (77 °F). Keep them in the original blister pack or container, protect from moisture and direct sunlight, and store out of reach of children. Do not refrigerate or freeze the tablets.

Imuran is taken orally as a tablet, usually with food or a glass of water to reduce gastrointestinal irritation. The tablet should be swallowed whole; it should not be crushed, chewed, or split unless specifically instructed by a healthcare professional. Dosing frequency and timing are determined by the prescribing clinician.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity, pancreatitis, opportunistic infections, and an increased long‑term risk of certain malignancies such as lymphoma or skin cancer. Patients should undergo regular blood count and liver‑function monitoring to detect these complications early.

Imuran is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, in those with active severe infections, and in pregnant women unless the therapeutic benefit outweighs fetal risk. It should also be avoided in individuals with severe hepatic impairment or in patients receiving live vaccines without appropriate medical supervision.